Osmotica Pharmaceuticals appoints new vice president

Osmotica Pharmaceuticals has appointed Samer Kaba as vice president and head of global clinical development and medical affairs.

Kaba brings experience in developing pharmaceutical products for neurology, analgesia, and autoimmune diseases and has spent 15 years in the pharmaceutical industry in global clinical development programmes from early to late stage development and submission of NDAs and global marketing authorisations.

Praveen Tyle, president and CEO of Osmotica, said: “We are very pleased to have Samer as part of our senior leadership team at such an exciting time as he will be instrumental in further progressing Osmotica's recent achievements in our two lead CNS product candidates – Ontinua ER and Osmolex ER.

“Dr. Kaba's experience in multiple sclerosis will also be instrumental in discussions with FDA for the approval of Ontinua ER, which was accepted for filing by the FDA recently.”